Literature DB >> 14769208

Hypoglycemic effect of Ganoderma lucidum polysaccharides.

Hui-na Zhang1, Zhi-bin Lin.   

Abstract

AIM: To investigate the hypoglycemic effect of Ganoderma lucidum polysaccharides (Gl-PS) in the normal fasted mice and its possible mechanism.
METHODS: Normal fasted mice were given a single dose of Gl-PS 25, 50, and 100 mg/kg by i.p. and the serum glucose was measured at 0, 3, and 6 h after administration. Gl-PS 100 mg/kg were also given by i.p. and the serum glucose and insulin levels were measured at 0 min, 30 min, 1 h, 3 h, 6 h, and 12 h. Pancreatic islets were isolated and incubated with glucose 5.6 mmol/L and different concentration of Gl-PS, the insulin content of islets and insulin release were examined. The islets fluorescent intensity of [Ca2+]i was also studied with a confocal microscope. Verapamil and egtazic acid were used to testify whether the insulin-releasing effect of Gl-PS was mediated by its ability to raise the Ca2+ influx.
RESULTS: Gl-PS dose-dependently lowered the serum glucose levels at 3 h and 6 h after administration. Gl-PS 100 mg/kg raised the circulating insulin levels at 1 h after administration. In vitro, Gl-PS had no effect on islets insulin content, but it stimulated the insulin release after incubation with glucose 5.6 mmol/L. Confocal microscope showed that Gl-PS 100 mg/L had the capacity to raise the [Ca2+]i. The insulin-releasing effect of Gl-PS was inhibited by verapamil/egtazic acid.
CONCLUSION: Gl-PS possesses the hypoglycemic effect on normal mice; one mechanism is through its insulin-releasing activity due to a facilitation of Ca2+ inflow to the pancreatic beta cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14769208

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  13 in total

Review 1.  Historical and current perspectives on therapeutic potential of higher basidiomycetes: an overview.

Authors:  Ruby Varghese; Yogesh Bharat Dalvi; Prasad Y Lamrood; Bharat P Shinde; C K K Nair
Journal:  3 Biotech       Date:  2019-09-17       Impact factor: 2.406

Review 2.  Misconstrued versatility of Ganoderma lucidum: a key player in multi-targeted cellular signaling.

Authors:  Balraj Singh Gill; Prateek Sharma; Raj Kumar; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2015-12-30

3.  Ganoderma lucidum inhibits inducible nitric oxide synthase expression in macrophages.

Authors:  Connie W H Woo; Ricky Y K Man; Yaw L Siow; Patrick C Choy; Eric W Y Wan; Chak S Lau; Karmin O
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

Review 4.  Traditional chinese medicine in treatment of metabolic syndrome.

Authors:  Jun Yin; Hanjie Zhang; Jianping Ye
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-06       Impact factor: 2.895

5.  Production, structural and biochemical characterization relevant to antitumor property of acidic exopolysaccharide produced from Bacillus sp. NRC5.

Authors:  Sahar S Mohamed; Abeer Y Ibrahim; Mohsen S Asker; Manal G Mahmoud; Samah A El-Newary
Journal:  Arch Microbiol       Date:  2021-06-10       Impact factor: 2.552

Review 6.  Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors.

Authors:  Nerida L Klupp; Dennis Chang; Fiona Hawke; Hosen Kiat; Huijuan Cao; Suzanne J Grant; Alan Bensoussan
Journal:  Cochrane Database Syst Rev       Date:  2015-02-17

7.  Antihepatoma and liver protective potentials of ganoderma lucidum ( ling zhi) fermented in a medium containing black soybean ( hēi dòu) and astragalus membranaceus ( shēng huáng qí).

Authors:  Zheng-Yuan Su; Lucy Sun Hwang; Been-Huang Chiang; Lee-Yan Sheen
Journal:  J Tradit Complement Med       Date:  2013-04

8.  Effect of Ganoderma lucidum hydroalcoholic extract on insulin release in rat-isolated pancreatic islets.

Authors:  Reza Shafiee-Nick; Seyyed Mohammad Reza Parizadeh; Nona Zokaei; Ahmad Ghorbani
Journal:  Avicenna J Phytomed       Date:  2012

Review 9.  Anti-Obesity Effects of Medicinal and Edible Mushrooms.

Authors:  Kumar Ganesan; Baojun Xu
Journal:  Molecules       Date:  2018-11-05       Impact factor: 4.411

10.  A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome.

Authors:  Nerida L Klupp; Hosen Kiat; Alan Bensoussan; Genevieve Z Steiner; Dennis H Chang
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.